Low-dose aspirin for the prevention of atherothrombosis

Article Abstract:

Atherosclerosis, the major cause of ischemic coronary artery disease and cerebrovascular disease, is a chronic inflammatory disorder in which immune mechanisms interact with metabolic risk factors. Randomized trials indicate that low-dose aspirin could prevent arterial thrombosis under various circumstances, including first vascular events among low-risk, healthy subjects and recurrent vascular events among patients with known acute or chronic occlusive vascular disease.

United States, Science & research, Research, Arterial occlusions, Arterial occlusive diseases

---

Daily aspirin--only half the answer

Article Abstract:

Aspirin may help reduce some of the symptoms of polycythemia vera but not all. People with polycythemia vera have too many red blood cells. This makes their blood thicker and also increases the risk of blood clot formation. Aspirin prevents blood clot formation, but it does not make blood thinner. For this reason, these patients should still be treated with regular phlebotomies, which is the medical term for blood donation.

Health aspects

---

Efficacy and safety of low-dose aspirin in polycythemia vera

Article Abstract:

Aspirin may be effective in preventing the complications of polycythemia vera, according to a study of 518 patients. People with polycythemia vera have too many red blood cells. This makes the blood thick and increases the risk of blood clots. In this study, patients who took aspirin were about 60% less likely to have a heart attack or stroke than patients who took a placebo, or inactive substance.

Evaluation

Similar abstracts:

• Abstracts: Deadline near for electronic payment of payroll taxes. Doctors see payoff in internal use of outcomes data
• Abstracts: Six ways to improve your practice. The revolution ... that never happened
• Abstracts: Time to close. Speech-recognition software improves, gains recognition
• Abstracts: Newspaper wins right to publish peer review. Visitation guidelines promote safe, satisfying environments
• Abstracts: Estrogen plus progestin and risk of venous thrombosis. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.